Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 13.1× sales vs its 10.4× historical median P/S.
Fair value ≈ $56.25 · price $70.98 today
Overvalued · 26% above
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$AXNX Axonics, Inc. (NASDAQ:AXNX): A Pioneering Force in Bladder and Bowel Dysfunction Management https://beyondspx.com/article/axonics-inc-nasdaq-axnx-a-pioneering-force-in-bladder-and-bowel-dysfunction-management
$AXNX At a special meeting held on March 22, 2024 the shareholders of Axonics, Inc. (AXNX) approved a merger with Boston Scientific Corp (BSX) . The merger is tentatively scheduled to close prior to the market open on November 15, 2024. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on November 14, 2024. If the merger closes as anticipated, the stock will remain halted on the day of closing (November 15th) and will be suspended effective November 18, 2024
https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2024-557
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Axonics Modulation Technologies Inc. Is that bullish or bearish? $AXNX #RsiOverbought #NASDAQ
$AXNX Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia
https://www.stocktitan.net/news/AXNX/axonics-receives-regulatory-approval-for-fourth-generation-3ovsgvazbyi0.html
$AXNX $MDT Axonics prevails in patent infringement lawsuit with Medtronic
Axonics (AXNX) announced that the jury has returned a unanimous verdict in the patent infringement lawsuit brought by Medtronic (MDT) against Axonics in U.S. District Court for the Central District of California. The jury found that Axonics does not infringe any of the three patents-in-suit. "A jury of our peers recognized that Axonics' proprietary tined lead design and temperature sensor technology is differentiated from our competitor's intellectual property," said Raymond W. Cohen, chief executive officer.
"As we have said since this case was first filed in late 2019, our view is that Medtronic's lawsuit was initiated to stifle competition, limit patient and physician choice, and protect the incumbent's monopoly in sacral neuromodulation. We are very pleased with the jury's finding and continue to remain focused on fulfilling our mission of positively impacting the lives of adults with bladder and bowel dysfunction."
$AXNX Axonics Prevails in Patent Infringement Lawsuit with Medtronic
https://www.stocktitan.net/news/AXNX/axonics-prevails-in-patent-infringement-lawsuit-with-8kt1pxdoa3dc.html
